Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term experience after AMT-060 gene therapy for haemophilia B
NL-OMON58404Not yet recruiting
- Sponsor
- Haemnet
- Start
- Mar 2026
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by Haemnet. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON58404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58404.